Literature DB >> 12821481

Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Victor E Buckwold1, Jiayi Wei, Michelle Wenzel-Mathers, Julie Russell.   

Abstract

Monotherapy of hepatitis C virus infection with either alpha interferon or ribavirin alone is rather ineffective, while the use of the two antivirals together is much more efficacious. In vitro drug-drug combination analysis utilizing related members of the family Flaviviridae, bovine viral diarrhea virus and yellow fever virus, revealed significant direct synergistic interactions between these drugs' antiviral activities that might explain this clinical observation.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12821481      PMCID： PMC161860          DOI： 10.1128/AAC.47.7.2293-2298.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  37 in total

1.  Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.

Authors:  W Markland; T J McQuaid; J Jain; A D Kwong
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.

Authors:  P Glue; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs; R P Clement
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

3.  Mechanism of action of a pestivirus antiviral compound.

Authors:  S G Baginski; D C Pevear; M Seipel; S C Sun; C A Benetatos; S K Chunduru; C M Rice; M S Collett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Authors:  Ana Maria Contreras; Yoichi Hiasa; Wenping He; Adam Terella; Emmett V Schmidt; Raymond T Chung
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 5.  Quasispecies, error catastrophe, and the antiviral activity of ribavirin.

Authors:  Jason D Graci; Craig E Cameron
Journal:  Virology       Date:  2002-07-05       Impact factor: 3.616

6.  The combination of interferon alpha-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy.

Authors:  Serguey Ouzounov; Anand Mehta; Raymond A Dwek; Timothy M Block; Robert Jordan
Journal:  Antiviral Res       Date:  2002-09       Impact factor: 5.970

7.  Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.

Authors:  Valérie Castet; Chantal Fournier; Alexandre Soulier; Rozenn Brillet; Joliette Coste; Dominique Larrey; Daniel Dhumeaux; Patrick Maurel; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Ribavirin quantification in combination treatment of chronic hepatitis C.

Authors:  Sylvie Larrat; Françoise Stanke-Labesque; Agnès Plages; Jean-Pierre Zarski; Germain Bessard; Claude Souvignet
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons.

Authors:  I Wayne Cheney; Vicky C H Lai; Weidong Zhong; Tessa Brodhag; Shannon Dempsey; Charmaine Lim; Zhi Hong; Johnson Y N Lau; Robert C Tam
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Ribavirin causes error catastrophe during Hantaan virus replication.

Authors:  William E Severson; Connie S Schmaljohn; Ali Javadian; Colleen B Jonsson
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103
View more
  14 in total

1.  Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.

Authors:  Jinhong Chang; Wouter Schul; Terry D Butters; Andy Yip; Boping Liu; Anne Goh; Suresh B Lakshminarayana; Dominic Alonzi; Gabriele Reinkensmeier; Xiaoben Pan; Xiaowang Qu; Jessica M Weidner; Lijuan Wang; Wenquan Yu; Nigel Borune; Mark A Kinch; Jamie E Rayahin; Robert Moriarty; Xiaodong Xu; Pei-Yong Shi; Ju-Tao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2010-11-10       Impact factor: 5.970

2.  Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.

Authors:  Jill Walker; Renae Crosby; Amy Wang; Ermias Woldu; Jessica Vamathevan; Christian Voitenleitner; Shihyun You; Katja Remlinger; Maoshang Duan; Wieslaw Kazmierski; Robert Hamatake
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Inhibition of bovine viral diarrhea virus RNA synthesis by thiosemicarbazone derived from 5,6-dimethoxy-1-indanone.

Authors:  Eliana F Castro; Lucas E Fabian; María E Caputto; Dolores Gagey; Liliana M Finkielsztein; Graciela Y Moltrasio; Albertina G Moglioni; Rodolfo H Campos; Lucía V Cavallaro
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

4.  Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model.

Authors:  Justin G Julander; Jane Ennis; Jeffrey Turner; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

5.  Host-directed Inhibitors of Myxoviruses: Synthesis and in vitro Biochemical Evaluation.

Authors:  Aiming Sun; J Maina Ndungu; Stefanie A Krumm; Jeong-Joong Yoon; Pahk Thepchatri; Michael Natchus; Richard K Plemper; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2011-08-23       Impact factor: 4.345

6.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

7.  Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus.

Authors:  David Durantel; Sandra Carrouée-Durantel; Norica Branza-Nichita; Raymond A Dwek; Nicole Zitzmann
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Development of one-step SYBR Green real-time RT-PCR for quantifying bovine viral diarrhea virus type-1 and its comparison with conventional RT-PCR.

Authors:  Ni Zhang; Zhengwen Liu; Qunying Han; Jianming Qiu; Jinghong Chen; Guoyu Zhang; Zhu Li; Sai Lou; Na Li
Journal:  Virol J       Date:  2011-07-29       Impact factor: 4.099

9.  Antiviral activity of Bacillus sp. isolated from the marine sponge Petromica citrina against bovine viral diarrhea virus, a surrogate model of the hepatitis C virus.

Authors:  Juliana Cristina Santiago Bastos; Luciana Konecny Kohn; Fabiana Fantinatti-Garboggini; Marina Aiello Padilla; Eduardo Furtado Flores; Bárbara Pereira da Silva; Cláudia Beatriz Afonso de Menezes; Clarice Weis Arns
Journal:  Viruses       Date:  2013-04-29       Impact factor: 5.048

10.  Asymmetric synthesis of host-directed inhibitors of myxoviruses.

Authors:  Terry W Moore; Kasinath Sana; Dan Yan; Pahk Thepchatri; John M Ndungu; Manohar T Saindane; Mark A Lockwood; Michael G Natchus; Dennis C Liotta; Richard K Plemper; James P Snyder; Aiming Sun
Journal:  Beilstein J Org Chem       Date:  2013-01-30       Impact factor: 2.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.